Active Research Studies at Corewell Health West

Adult Pulmonary	
Critical Care	
I-SPY COVID Trial NCT04488081	An Adaptive Platform Trial to Reduce Mortality and Ventilator Requirements for Critically III Patients
Cystic Fibrosis	
YMCA 3 Minute Step Test in Adults with Cystic Fibrosis	Feasibility and Reliability of the YMCA 3 Minute Step Test in Adults with Cystic Fibrosis
MAYFLOWERS-OB-20	Maternal and Fetal Outcomes in the Era of Modulators
Hypertension	
Arena 301/Advance Outcomes	A StuDy eVAluatiNg the EffiCacy and Safety of RalinEpag To Improve Treatment OUTCOMES in PAH Patients
Pulmonary	
VBI-S-02	VBI-S for the treatment of Hypotension in Hypovolemic Septic Shock Patients
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS- 986278 in Participants with Idiopathic Pulmonary Fibrosis	A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Idiopathic Pulmonary Fibrosis

Topic: MK-5475 Protocol 013: A Phase 2a, Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of MK-5475 in Adults with Pulmonary Hypertension associated with Chronic Obstructive Pulmonary Disease

A Phase 2a, Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of MK-5475 in Adults with Pulmonary Hypertension associated with Chronic Obstructive Pulmonary Disease

Arena 303	A StuDy EVAluatiNg the Long-Term EffiCacy and Safety of RalinEpag in Subjects with PAH via an Open-Label EXTENSION
RejuvenAIR Spray CB	A Prospective Sham Controlled Randomized Clinical Trial of the RejuvenAir™ System for the Treatment of Moderate to Severe Chronic Obstructive Pulmonary Disease with Chronic Bronchitis
NCT05158387	A phase III Randomized, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled study to evaluate the efficacy and safety of two dose regimens of MEDI3506 in participants with COPD.
Pulmonary Sarcoidosis 2022-001012-26	A multicenter, randomized, double-blinded, placebo-controlled, study compairing the efficacy and safey of Intravenous(IV) efzofitimod 3 mg/kg and 5 mg/kg versus placebo after 48 weeks of treatment in patients with pulmonary sarcoidosis.